Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan-based dual H. pylori eradication vs PPI for prevention of gastrointestinal bleeding in ACS patients post-PCI
ChiCTR2500110755Phase 4Completed
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vonoprazan in Helicobacter pylori infection, gastrointestinal bleeding and acute coronary syndrome (ACS) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Gastrointestinal bleeding and H. pylori eradication status. Started Oct 2025; status: completed.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infectiongastrointestinal bleedingacute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR2500110755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110755.